Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.85

-4.5%

Jan 9 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (6419)	5/23/2002 4:32:51 PM
From: Czechsinthemail	Read Replies (1) of 52153

I can understand the dissension on Amevive. I'm told its side effects may include impacting certain immune system functions. Since psoriasis isn't life threatening, I could understand those reviewing it being cautious. I'm not an owner of BGEN, but I'm certainly glad to see the rest of my biotech portfolio getting goosed following the announcement. What do you think is the likelihood of the FDA overturning the AC recommendation? And do you think it is likely to have a negative effect on other companies trying to get psoriasis drugs approved by effectively raising the crossbar for those following in the wake of Amevive?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next